'Old-for-old' - New strategies for renal transplantation

Nephrology Dialysis Transplantation

Volumn 22, Issue 2, 2007, Pages 336-341

  Arns, Wolfgang ^a   Citterio, Franco ^b   Campistol, Josep M ^c  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

'Old for old'; Calcineurin inhibitor; Everolimus; Proliferation signal inhibitors mTOR inhibitors; Renal transplantation

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; AGE DISTRIBUTION; CANCER RISK; CARDIOVASCULAR RISK; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAINTENANCE THERAPY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME;

AGE FACTORS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PRACTICE GUIDELINES; PROGNOSIS; TISSUE DONORS;

EID: 33846693823     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl637     Document Type: Review

References (43)

1. Cohen B, Smits JM, Haase B, Persijn G, Vangenterghem Y, Frei U. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transplant 2005; 20: 34-41
2. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor analysis. Transplantation 2002; 74: 1377-1381
3. Gallon LG, Leventhal JR, Kaufman DB. Pretransplant evaluation of renal transplant candidates. Semin Nephrol 2002; 22: 515-525
4. Port FK, Bragg-Gresham JL, Metzger RA et al. Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281-1286
5. Ojo AO, Hanson JA, Meier-Kriesche HU et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589-597
6. Waiser J, Schreiber M, Budde K et al. Age-matching in renal transplantation. Nephrol Dial Transplant 2000; 15: 696-700
7. Smits JMA, Persijn GG, van Houwelingen HC, Claas FHJ, Frei U. Evaluation of the eurotransplant senior program. The results of the first year. Am J Transplant 2002; 2: 664-670
8. Oppenheimer F, Aljama P, Peinado CA et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004; 19 [Suppl 3]: 11-15
9. Fabrizii V, Kovarik J, Bodingbauer M et al. Long-term patient and graft survival in the Eurotransplaut Senior Program: A single-center experience. Transplantation 2005; 80: 582-589
10. Eurotransplant Annual Reports 1996-2003. http://www.eurotransplant.nl/ ?id=annual_report
11. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med 1986; 80: 435-42
12. Kumar MSA, Stephan R, Chui J et al. Donor age and graft outcome in cadaver renal transplantation. Transplant Proc 1993; 25: 3097-3098
13. Basar H, Soran A, Shapiro R et al. Transplantation in recipients over the age of 60: The impact of donor age. Transplantation 1999; 67: 1191-1193
14. Collaborative Transplant Study. http://www.ctstransplant.org
15. de Fijter JW, Mallat MJK, Doxiadis IIN et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12: 1538-1546
16. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in autoimmune diseases. N Eng J Med 1992; 326: 1654-1660
17. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291-1295
18. Meier-Kriesche HU, Ojo AO, Cibrik DM et al. Relationship of recipient age and development of chronic allograft failure. Transplantation 2000; 70: 306-310
19. Meier-Kriesche HU, Ojo AJ, Hanson JA, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539-1543
20. Ponticelli C. Guest editor's introduction. Transplantation 2005; 79: S69-S71
21. Doyle SE, Matas AJ, Gillingham K, Rosenberg ME. Predicting clinical outcome in the elderly renal transplant recipient. Kidney Int 2000; 57: 2144-2150
22. Pascual J, Marcen R, Ortuno, J. Clinical experience with everolimus (Certican®) in elderly recipients: The 'old-for-old' concept. Transplantation 2005; 79: S85-S88
23. Schuurman HJ, Cottens S, Fuchs S et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplantation 1997; 64: 32-35
24. Vitko Š, Margreiter R, Weimar W et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521-2530
25. Lorber MI, Mulgaonkar S, Butt KM et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244-252
26. Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961
27. Bonegio R, Lieberthal W. Role of apoptosis in the pathogenesis of acute renal failure. Curr Opin Nephrol Hypertens 2002; 11: 301-308
28. Vítko Š, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635
29. Pascual J. Concentration-controlled everolimus (Certican®): Combination with reduced dose calcineurin inhibitors. Transplantation 2005b; 79: S76-S79
30. Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systemic review of randomized trials. Am J Transplant 2005; 5: 1748-1756
31. Rapamune® Prescribing Information. Philadelphia: Wyeth Pharmaceuticals Inc, 2006
32. Coombes JD, Mreich E, Liddle C, Rangan GK. Rapamycin worsens renal function and intratubular cast formation in protein overload nephropathy. Kidney Int 2005; 68: 2599-2607
33. Diekmann F, Budde K, Oppenheimer F et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant. 2004; 4: 1869-1875
34. Bumbea V, Kamar N, Ribes D et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517-2523
35. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003; 35 [3 Suppl]: 52S-57S
36. Budde K, Glander P, R Schuhmann R et al. Improvement in renal function and pharmacokinetic changes after conversion from cyclosporine to everolimus. Presented at Australian Society for Clinical and Experimental Pharmacologists and 'Old-for-old' - new strategies for renal transplantation Toxicologists (ASCEPT), 4th-7th December 2005, Melbourne, Australia
37. Arns W, Glander P, Schuhmann R et al. Conversion from tacrolimus to everolimus does not influence the pharmacokinetic and the pharmacodynamic of mycophenolate sodium in renal transplant patients. Presented at Australian Society for Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), 4th-7th December 2005, Melbourne, Australia
38. Arbogast H, Hückelheim H, Schneeberger H et al. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: long-term results from a prospective single centre trial. Clin Transplant 2005; 19: 309-315
39. Webster AC, Lee VWS, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systemic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248
40. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
41. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
42. Pascual J, Fernández AM, Marcén R, Ortuño J. Conversion to everolimus in a patient with hypertension and recurrent cutaneous neoplasia - a case report. Nephrol Dial Transplant 2006; 21 [Suppl 2]: iii38-iii41
43. Sparacino V, Calabrese S. Conversion to a proliferation signal inhibitor in a patient with coronary artery disease - a case report. Nephrol Dial Transplant 2006; 21 [Suppl. 2]: Iii34-ii37